Matching Placebo for Deucravacitinib clinical trials

A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis

This study is testing a new medicine, Zasocitinib (TAK-279), for people with moderate to severe plaque psoriasis. It compares it to an existing medicine, Deucravacitinib (SOTYKTU), and a dummy pill to see how well it works, if it's safe, and how people tolerate it.